Nasdaq · Healthcare
Lipocine Inc. (LPCN)
As-reported financials and recent SEC filings for Lipocine Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.0M
Net income
$-9.6M
Net margin
—
Diluted EPS
$-1.69
ROE
-66.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $11.2M | $-2.9M | $500,000 | $16.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $-10.4M | $-1.2M | $-17.9M | $-12.1M | $3.1M |
| Net income | $-9.6M | $8,352 | $-16.4M | $-10.8M | $-634,399 |
| Diluted EPS | $-1.69 | — | $-3.14 | $-2.15 | $-0.17 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-30
View on EDGAR →8-K2026-06-12
View on EDGAR →S-82026-06-09
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →8-K2026-06-04
View on EDGAR →Largest Healthcare peers
Go deeper on LPCN
Search Lipocine Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.